Q2 FY2026 EarningsQ2 FY26 missed consensus expectations on both top and bottom lines, with revenue of $19.3M falling short of the $20.0M estimate (-4% YoY). Despite a 2.30pct gross margin beat (72.2% actual vs. 69.9% expected), net loss widened to $11.3M compared to the $10.5M consensus, primarily due to higher interest expenses and weak OviTex PRS volume. Management took the drastic step of withdrawing full-year 2026 revenue guidance, citing the need for a strategic reassessment under new leadership.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Tela Bio(TELA) the Revenue is 19.29 M (-4.49%), Miss estimate;the EBIT is -9.283 M (-2.22%), Miss estimate;the EPS is -0.2 (+9.09%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.02B4.49%
0.02B0.93%
-0.00B3.56%
EBITMiss expectations
-0.01B2.22%
-0.01B0.29%
-0.00B2.51%
EPSMiss expectations
-0.29.09%
-0.173321.21%
-0.026712.12%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf